Daily Endocrinology Research Analysis
Direct-to-patient screening substantially increased identification of primary aldosteronism and facilitated initiation of targeted therapy. A meta-analysis shows postpartum lifestyle interventions reduce progression to type 2 diabetes after gestational diabetes, with greatest benefit in high-risk women. Histopathological subtyping of non-functioning pituitary adenomas by transcription factor immunohistochemistry correlates with invasive behavior, informing prognosis and management.
Summary
Direct-to-patient screening substantially increased identification of primary aldosteronism and facilitated initiation of targeted therapy. A meta-analysis shows postpartum lifestyle interventions reduce progression to type 2 diabetes after gestational diabetes, with greatest benefit in high-risk women. Histopathological subtyping of non-functioning pituitary adenomas by transcription factor immunohistochemistry correlates with invasive behavior, informing prognosis and management.
Research Themes
- Implementation science in endocrine screening
- Postpartum diabetes prevention
- Molecular pathology-driven risk stratification
Selected Articles
1. Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program.
In a nationwide pragmatic program (n=694), 25.4% of hypertensive adults screened positive for primary aldosteronism through direct-to-patient testing, despite 57% already being under specialist care. Among positives, 13.7% initiated aldosterone-targeted therapy and 24.5% reported improved blood pressure, demonstrating feasibility and clinical yield of scalable remote screening.
Impact: This study provides a scalable solution to the major screening gap in primary aldosteronism and demonstrates real-world treatment initiation and BP benefits. It aligns with new guidelines recommending universal screening in hypertension.
Clinical Implications: Health systems can adopt direct-to-patient workflows (remote consent, local labs, standardized interpretation) to increase primary aldosteronism detection and expedite mineralocorticoid receptor antagonist use or surgical referral. Primary care and specialty clinics should integrate streamlined testing for patients with resistant hypertension, hypokalemia, or sleep apnea.
Key Findings
- 25.4% of 694 hypertensive participants screened positive for primary aldosteronism using a standardized, direct-to-patient algorithm.
- Despite specialty care (endocrinology/cardiology/nephrology) in 57% of participants, most had not previously been tested for primary aldosteronism.
- Among those with positive results, 25.5% underwent additional testing, 13.7% started aldosterone-targeted therapy, and 24.5% reported improved blood pressure.
- Common indications for testing were sleep apnea, resistant hypertension, and hypokalemia; over half had ≥2 indications.
Methodological Strengths
- Pragmatic, nationwide implementation with remote consent and standardized diagnostic algorithm.
- Real-world follow-up capturing additional testing, therapy initiation, and patient-reported blood pressure outcomes.
Limitations
- Nonrandomized design with potential selection bias from online recruitment.
- Incomplete uptake of downstream confirmatory testing and therapy; outcomes limited to 6–12 months follow-up.
Future Directions: Head-to-head comparisons of direct-to-patient versus clinic-based workflows, cost-effectiveness analyses, and integration with electronic health record prompts to scale universal primary aldosteronism screening.
BACKGROUND: Primary aldosteronism, an endocrinopathy present in ≥10% to 25% of patients with hypertension, confers excess cardiovascular risk that can be mitigated with aldosterone-directed therapy. However, only 2% of eligible patients undergo guideline-recommended screening. This study aimed to bypass clinical inertia and identify people with primary aldosteronism using pragmatic, direct-to-patient testing. METHODS: Hypertensive adults were recruited via online platforms and underwent virtual consent and local phlebotomy. Using a standardized diagnostic algorithm, laboratory results with interpretations were communicated to patients and primary care providers. Follow-up was ascertained at 6 to 12 months. The primary outcome was the frequency of a positive test for primary aldosteronism. Secondary outcomes included follow-up primary aldosteronism testing and implementation of aldosterone-targeted therapies. RESULTS: The study population (N=694) had a mean age of 63.3±11.3 years, was 52.2% female, and hailed from 41 US states. Overall, 25.4% had a positive test for primary aldosteronism. Sleep apnea, resistant hypertension, and hypokalemia were the most common testing indications, with 55.2% of participants having ≥2 indications. Over half of participants (57%) were already under endocrinology, cardiology, or nephrology care, yet had not been tested. In longitudinal follow-up of participants with a positive result, 25.5% had additional testing, 13.7% were started on aldosterone-targeted therapy (mineralocorticoid receptor antagonist or adrenalectomy), and 24.5% reported improved blood pressure control. CONCLUSIONS: Pragmatic, direct-to-patient testing, and simplified results interpretation is a feasible, scalable method to increase primary aldosteronism diagnoses and implementation of aldosterone-targeted therapies. Given that new hypertension guidelines recommend primary aldosteronism screening in all hypertensive people, practical approaches to test, interpret, and implement results will be essential.
2. Lifestyle intervention to prevent type 2 diabetes after a pregnancy complicated by gestational diabetes mellitus: a systematic review and meta-analysis update.
Across 24 RCTs (n=9017), postpartum lifestyle interventions reduced incident type 2 diabetes by 19% overall (RR 0.81) and more strongly in high-risk women (RR 0.78), with NNT 31 in high-risk subgroups. Benefits occurred despite only modest weight differences, underscoring glycemic benefits beyond weight loss.
Impact: Provides high-level evidence to implement early postpartum prevention pathways after GDM, prioritizing high-risk women for maximal absolute benefit.
Clinical Implications: Postpartum care should include structured lifestyle programs soon after GDM pregnancy, with risk stratification to target women at highest risk where NNT is lowest. Even modest weight changes confer meaningful diabetes risk reduction.
Key Findings
- Lifestyle interventions after GDM reduced incident type 2 diabetes by 19% in lower-bias trials (RR 0.81, 95% CI 0.71–0.93).
- Greater benefit in high-risk women (RR 0.78) versus unselected GDM populations (RR 0.85; not statistically significant).
- Number needed to treat was 31 in high-risk women versus 71 in unselected GDM populations.
- Weight change was modest (−0.88 kg overall), indicating benefits beyond substantial weight loss.
Methodological Strengths
- Systematic review and meta-analysis of randomized controlled trials with PRISMA adherence and GRADE assessment.
- Sensitivity analyses and exclusion of high risk-of-bias studies support robustness of the findings.
Limitations
- Heterogeneity in timing, intensity, and components of interventions across trials.
- Follow-up durations and ascertainment methods vary; some trials had risk of bias.
Future Directions: Design pragmatic, culturally tailored postpartum programs integrated into obstetric and primary care workflows, with cost-effectiveness and implementation evaluations focusing on high-risk women.
BACKGROUND: Women with prior gestational diabetes mellitus (GDM) are at increased risk of type 2 diabetes, and lifestyle intervention (LSI) offered a decade after pregnancy is effective in preventing diabetes. However, since diabetes frequently onsets in the initial years following pregnancy, preventive actions should be implemented closer to pregnancy. We aimed to assess the effect of lifestyle interventions, compared to standard care, in reducing the incidence of diabetes following a pregnancy complicated by GDM. METHODS: We searched the Cochrane Library, Embase, MEDLINE, and Web of Science from inception to July 21, 2024, to identify randomized controlled trials (RCTs) testing LSI to prevent diabetes following gestational diabetes. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We evaluated the risk of bias with the Cochrane Collaboration Risk of Bias tool RoB-2 and the certainty of the evidence with GRADE methodology. We used the DerSimonian-Laird random effects pooling method and evaluated heterogeneity with the I RESULTS: We identified 24 studies involving 9017 women. In studies without high risk of bias (18 studies; 8,357 women), LSI reduced the incidence of diabetes by 19% (RR = 0.81; 95%CI 0.71.0.93). The effect was significant and more protective (RR = 0.78; 0.65, 0.94) in studies evaluating women with GDM identified specifically as at a higher risk of diabetes, compared to those intervening on women with GDM irrespective of risk (RR = 0.85; 0.70, 1.04). Similarly, when expressed in absolute terms, the overall number needed to treat (NNT) was 56 considering all studies, 71 for women with GDM irrespective of risk, and 31 for women with GDM at high risk. The intervention produced a lower weight gain (mean difference=-0.88 kg;-1.52, -0.23 for all studies; -0.62 kg;-1.22, -0.02 for studies without high risk of bias). The effects were robust in sensitivity analyses and supported by evidence of moderate certainty for diabetes and weight change. CONCLUSIONS: LSI offered to women with GDM following pregnancy is effective in preventing type 2 diabetes, despite the small postpartum weight change. The impact of LSI on incidence reduction was greater for women with GDM at a higher diabetes risk. PROSPERO: Registration number CRD42024555086, Jun 28, 2024.
3. Cell Lineage-Specific Differences in Clinical Behavior of Non-Functioning Pituitary Adenomas.
This systematic review/meta-analysis (27 studies) shows that non-functioning pituitary adenomas classified by transcription factor IHC exhibit distinct invasive profiles: cavernous sinus invasion is more prevalent in null cell adenomas and TPIT+ tumors versus SF1+, and higher in null cell adenomas versus PIT1+. Data for recurrence and radiotherapy were insufficient for pooling.
Impact: Integrates the 2017 WHO classification into clinical risk stratification by linking TF-defined subtypes with invasion patterns, informing surgical planning and follow-up.
Clinical Implications: Transcription factor IHC (SF1, PIT1, TPIT) should be implemented routinely for NFPAs to anticipate cavernous sinus invasion and tailor surgical approach, counseling, and surveillance intensity.
Key Findings
- Cavernous sinus invasion is more prevalent in null cell adenomas (NCAs) versus SF1+ NFPAs (PRR 1.60) and versus PIT1+ NFPAs (PRR 1.44).
- TPIT+ NFPAs show higher cavernous sinus invasion compared with SF1+ NFPAs (PRR 1.43).
- Limited data precluded pooled analyses for recurrence and radiotherapy outcomes.
Methodological Strengths
- Comprehensive multi-database search with QUIPS risk-of-bias assessment.
- Random-effects models with reporting of prediction intervals and low heterogeneity for key comparisons.
Limitations
- Underlying evidence consists of observational cohorts with potential confounding.
- Insufficient studies for meta-analysis of recurrence and radiotherapy; evolving classification may introduce misclassification.
Future Directions: Prospective registries integrating TF IHC, radiogenomics, and standardized outcomes (invasion, recurrence) to refine prognostic models and guide adjuvant therapy trials.
CONTEXT: Immunohistochemistry (IHC) of cell lineage-specific transcription factors (TFs) has been added to the histopathological classification of pituitary adenomas since 2017, resulting in new histopathological subtypes of TF+/hormone-non-functioning pituitary adenomas (NFPAs) and a reduction in the prevalence of null cell adenomas (NCAs). OBJECTIVE: This work aimed to evaluate associations between expression of cell lineage-specific TFs by IHC and radiological invasion and prognosis of NFPAs. DATA SOURCES: A literature search in Medline, Embase, and CENTRAL was performed from inception up to July 11, 2023. STUDY SELECTION: Eligible studies were cohort studies reporting on radiological invasion, recurrence, and/or radiotherapy in patients with NFPAs who tested positive for one cell lineage-specific TF or negative for all 3. Finally, 27 out of 1985 studies were included. DATA EXTRACTION: Two authors independently extracted data and critically appraised risk of bias using the Quality In Prognostic Studies (QUIPS) tool. DATA SYNTHESIS: Random-effects inverse variance models were used to pool effect sizes. Prevalence rate ratios (PRRs) were calculated using the Mantel-Haenszel method. Cavernous sinus invasion was more prevalent in NCAs and TPIT+ NFPAs compared with SF1+ NFPAs (PRR 1.60; 95% CI, 1.22-2.08, I2 10%, 95% prediction interval [PrI] 1.23-2.06; P = .0036, and PRR 1.43; 95% CI, 1.21-1.70, I2 0%, 95% PrI 1.17-1.76; P = .0017, respectively), and in NCAs compared with PIT1+ (PRR 1.44; 95% CI, 1.01-2.06, I2 0%, 95% PrI 0.83-2.50; P = .0454). A limited number of studies precluded data syntheses of recurrence and radiotherapy. CONCLUSION: The use of cell lineage-specific TFs by IHC enables to detect histopathological subtypes of NFPAs with distinct clinical behavior.